CancerVax Ends Development of Melanoma Vaccine Canvaxin
This article was originally published in The Pink Sheet Daily
Executive Summary
CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.